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Background: The progression of chronic obstructive pulmonary disease (COPD) considerably varies among patients.
Those with emphysema identified by quantitative computed tomography (CT) are associated with the rapid
progression assessed by forced expiratory volume in one second (FEV1). However, whether the rate of the decline in
lung function is independently affected by the regional distribution or the severity of emphysema in the whole
lung is unclear.
Methods: We followed up 131 male patients with COPD for a median of 3.7 years. We measured wall area percent
(WA%) in right apical segmental bronchus, total lung volume, percent low attenuation volume (LAV%), and the
standard deviation (SD) of LAV% values from CT images of 10 isovolumetric partitions (SD-LAV) as an index of
cranial-caudal emphysema heterogeneity. Annual changes in FEV1 were then determined using a random
coefficient model and relative contribution of baseline clinical parameters, pulmonary function, and CT indexes
including LAV%, SD-LAV, and WA% to annual changes in FEV1 were examined.
Results: The mean (SD) annual change in FEV1 was −44.4 (10.8) mL. Multivariate random coefficient model showed
that higher baseline FEV1, higher LAV%, current smoking, and lower SD-LAV independently contributed to an
excessive decline in FEV1, whereas ratio of residual volume to total lung capacity, ratio of diffusing capacity to
alveolar ventilation, and WA% did not, after adjusting for age, height, weight, and ratio of CT-measured total lung
volume to physiologically-measured total lung capacity.
Conclusions: A more homogeneous distribution of emphysema contributed to an accelerated decline in FEV1
independently of baseline pulmonary function, whole-lung emphysema severity, and smoking status. In addition to
whole-lung analysis of emphysema, CT assessment of the cranial-caudal distribution of emphysema might be useful
for predicting rapid, progressive disease and for developing a targeted strategy with which to prevent disease
progression.
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Figure 1 Protocol of the present study.
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Chronic obstructive pulmonary disease (COPD) is a
leading cause of death that is characterized by airflow
limitation [1]. Forced expiratory volume in one second
(FEV1) is central to assess airflow limitations and diag-
nose COPD, and the decline in FEV1 is one of the most
important outcome measures for evaluating disease pro-
gression in longitudinal observational studies and clinical
trials [2-5]. On the other hand, the clinical manifestation
of COPD is rather heterogeneous in terms of imaging
and disease progression [6,7]. Changes in FEV1 might
also vary among patients [4,7,8].
Identifying subgroups with different prognostic or
therapeutic characteristics as a specific phenotype is im-
portant to improve COPD management [6]. Several
reports have shown that quantitative computed tomog-
raphy (CT) is useful for phenotyping patients with
COPD because it provides structural information about
emphysematous change, airway dimensions and lung
volume [9-11]. Especially, since emphysema and airway
disease are two major features of COPD and the relative
involvement of these two factors considerably vary among
patients with COPD, the utility of CT-based categorization
(emphysema-predominant, airway-predominant, or mixed)
is being increasingly recognized [12-15]. Indeed, it has been
shown that CT findings of emphysema, but not airway wall
thickening correlate with low body mass index [13], and
that both CT measures of emphysema and airway disease
are associated with respiratory symptoms and frequency of
COPD exacerbations [14,16]. We previously demonstrated
that the extent of emphysema assessed by CT predicts
mortality in patients with COPD independently of FEV1
[17]. Moreover, the decline in FEV1 is greater in patients
with, than without the emphysema phenotype [4] and
emphysema severity is associated with a rapid annual
decline in FEV1 [8]. These findings indicate that the CT-
based emphysema phenotype provides information when
monitoring patients with COPD.
In addition to the whole lung quantitation of emphy-
sema, CT imaging can quantify the distribution of
emphysematous change [18-20]. Quantitative CT studies
have shown that the rates of homogeneous emphysema
distribution and of lower lung-predominant emphysema
in patients with COPD are not as small as estimated
from visual assessment [20,21]. Upper lung-dominant
emphysema is associated with genetic variants in MMP-
9 [22] or EPHX1 and GSTP1 [23] and the cranial-caudal
emphysema distribution is a powerful predictor of the
response to lung volume reduction surgery [24]. More-
over, lower lung-dominant emphysema can predict mor-
tality in patients with emphysema independently of
emphysematous changes in the whole lung [25]. These
findings suggest that the cranial-caudal heterogeneity of
emphysema can be used to further categorize patientswith the emphysema phenotype. However, whether
regional emphysema heterogeneity affects the rate of
disease progression remains unclear.
The present study investigates whether the cranial-
caudal heterogeneity of emphysema affects the decline in
FEV1 independently of the total amount of emphysema-
tous change. We followed up 131 male patients with
COPD for a median period of 3.7 years, and annual
changes in FEV1 were calculated using a random coeffi-
cient model. We then investigated which factors at study
entry can contribute to the decline in FEV1.Methods
Study design and study population
The protocol of this investigation, which was part of an
ongoing COPD observational study at Kyoto University, is
summarized in Figure 1. Some patients had also partici-
pated in our previous studies [10,26,27]. We recruited 163
patients with stable COPD between March 2006 and
August 2008 from an outpatient clinic at Kyoto University
Hospital. Exclusion criteria comprised a history of chest
disease other than COPD, refusal to undergo CT scanning
or a diagnosis of α1-antitrypsin deficiency. We excluded
18 patients with abnormal shadows not associated with
emphysematous changes in chest CT images at study
entry. We also excluded female patients because the
number of female patients (n= 9) was too small to
determine the impact of sex on pulmonary function
decline. Thus, 136 male patients who were examined by
spirometry every six months were followed up until July
2011. The rate of decline in lung function was analyzed
in a dataset of patients in whom FEV1 was measured at
least twice as described below. The ethics committee of
Kyoto University approved the study (approval No.
E182) and all patients provided written informed
consent to participate.
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During exacerbation-free periods, the patients inhaled
short-acting bronchodilators and then underwent pul-
monary function tests (Chestac-65 V; Chest MI Corp;
Tokyo, Japan) and high resolution CT at full inspiration
(Aquilion 64; Toshiba; Tokyo, Japan; 0.5-mm slice thick-
ness) as described [10,28]. Lung volumes and diffusion
capacity were measured by helium dilution and the
single-breath method, respectively. The use of only one
CT scanner avoided inter-scanner variability, and CT
parameters were analysed using a custom-designed
application [10]. We defined exacerbation of COPD as
symptomatic deterioration requiring antibiotics and/or
systemic corticosteroid. In patients who had been
followed up at Kyoto University Hospital during the year
before study entry, exacerbations were counted.
Analysis of CT images
We measured total lung volume, the ratio of low
attenuation volume to the lung volume (LAV%) in
the whole lung with −960 HU as the cut-off level,
and wall area percent (WA%) in the right apical seg-
mental bronchus as described [9,10,28,29]. By modify-
ing the reported method [16,30], we estimated the
level of inspiration during CT scanning. The ratio of
CT-derived total lung volume to physiologically-mea-
sured total lung capacity (TLC) was calculated as a
proxy for inspiration level, and the proxy was used
for statistical analysis. Total lung volume was divided
into equal upper and lower regions, and the differ-
ence in LAV% between the two regions was calcu-
lated as described [18,25]. Positive and negative
values for differences represent the upper and lower
dominance of emphysema, respectively.
To assess the cranial-caudal heterogeneity of emphy-
sema, we calculated standard deviation (SD) of values of
LAV% in 10 partitions with equal volume (SD-LAV) using
a modification of the reported method [19] as follows. As
shown in Figure 2, each lung was divided into 12 equal
volumes from the top to the base, and the most apical and
basal partitions were excluded to eliminate the volume
partial effect. Low attenuation volume was measured in
each partition. After summing low attenuation volumes of
identical partitions in the right and left lungs, LAV% in
each partition was measured by dividing the summed
value by the volume of the partition. Then, the SD of LAV
% values in the 10 partitions was calculated to obtain SD-
LAV. Higher and lower SD-LAV represent the more
heterogeneous and homogeneous distribution of emphy-
sema, respectively.
Statistical analyses
Data are expressed as means ± SD. Individual annual
changes in FEV1 were determined from empiricalBayes estimates using a random coefficient model
with a linear term of time and random effects of
intercepts and slopes for each patient. We assessed
the relative contributions of LAV% and SD-LAV to
the annual decline in FEV1 using a random coeffi-
cient model that included baseline age, height,
weight, percent predicted FEV1 (%FEV1), ratio of
residual volume to TLC (RV/TLC), ratio of diffusing
capacity to alveolar ventilation (DLCO/VA), smoking
status, LAV%, SD-LAV, WA%, and the proxy for
inspiration, and the interaction of each covariate with time.
A history of frequent exacerbations (≥ 2 exacerbations per
year) was not included in the analysis of all the enrolled
patients, because 12 of them had not been followed up in
the previous year, and they were included only in a supple-
mentary analysis. All p-values are two-sided and p< 0.05
was considered significant. All data were statistically ana-
lysed using JMP 7 software (SAS Institute, Cary, NC, USA).
Results
Characteristics of patients
Figure 1 shows that we excluded 5 of the 136 enrolled
patients without follow-up spirometry. The median
follow-up period was 3.7 years, and detailed information
about follow-up spirometry, the follow-up period, use of
regular COPD medication and clinical course are
provided in Supplementary Table E1, E2, and E3
(Additional file 1). We found that of 119 (91%) patients
whose history of exacerbations was recorded for one year
before study entry, 15 had experienced at least two
exacerbations.
The baseline characteristics of patients and CT
parameters are shown in Table 1. SD-LAV% significantly
correlated with the absolute value of the difference in LAV%
between the upper and lower lung regions
(r=0.94, p< 0.001), indicating that a higher SD-LAV% was
associated with more upper or lower predominant
emphysema.
Annual change in FEV1 and baseline quantitative CT
measurements
The mean (SD) annual change in FEV1 was −44.4 (10.8)
mL (Figure 3). The multivariate random coefficient
model showed that a higher %FEV1, current smoking,
higher LAV% in the whole lung, and lower SD-LAV in-
dependently contributed to the annual decline in FEV1,
whereas RV/TLC, DLCO/VA, and WA% did not, after ad-
justment for age, height, weight, and the proxy for inspir-
ation (Table 2). The findings of this analysis revealed
that a 1% increase in each of %FEV1 and LAV%, and a
1% decrease in SD-LAV contributed to an additional de-
cline of 0.97, 2.46, and 3.24 mL, respectively. The annual
decline in FEV1 was 20.90 mL greater in current, than in
former smokers. Our analysis of 119 (91%) patients
Figure 2 Illustration of the methods to evaluate the cranial-caudal heterogeneity of emphysematous change. Each lung was divided into
12 partitions with equal volumes (A), and LAV% values in 12 partitions were calculated (B). The top and basal partitions (open circles in C and D)
were excluded to avoid volume partial effects. SD-LAV was defined as the standard deviation of LAV% values in the remaining 10 partitions. C and
D showed examples of heterogeneous and homogeneous emphysema, respectively. While LAV% in C and D were almost similar (45.5 and 47.7%,
respectively), SD-LAV in C was higher than in D (8.0 versus 2.8%).
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with changes in FEV1, whereas a history of frequent
exacerbations did not (Table 3).Table 1 Baseline characteristics of study patients (n = 131)
Age (y) 70.7 ± 8.8
Height (cm) 164.4 ± 6.1
Weight (kg) 58.1 ± 8.9
Smoking status (current: former) 34 : 97
Smoking history (pack-years) 67.7 ± 34.1
Pulmonary function
FEV1 (L) 1.63 ± 0.68
%FEV1 (%) 57.9 ± 19.8
RV/TLC (%) 43.3 ± 8.1
DLCO/VA (mL/min/mmHg/L) 2.77 ± 1.08
CT parameters
LAV% (%) 33.0 ± 8.6
Total lung volume (L) 5.38 ± 0.9
Proxy for inspiration 0.93 ± 0.13
WA (right apical bronchus %) 57.8 ± 5.8
SD-LAV (%) 4.1 ± 2.5
Difference in LAV% (upper – lower lung)
≥ 0% (upper predominant) n = 94
<0% (lower predominant) n = 37
Data are expressed as means ± SD.
Abbreviations: FEV1, forced expiratory volume in one second;
%FEV1, FEV1% predicted; RV/TLC, ratio of residual volume to total lung capacity;
DLCO/VA, ratio of diffusing capacity to alveolar ventilation; LAV%, ratio of
low attenuation volume to total lung volume; WA%, wall area percent in right
apical bronchus;
Proxy for inspiration was defined as the ratio of CT-derived total lung volume
to physiologically measured total lung capacity;
SD-LAV, standard deviation of LAV% values in 10 partitions with equal volumes.Discussion
The present study found that in addition to LAV%,
smoking status, and baseline %FEV1, cranial-caudal
emphysema heterogeneity (assessed by SD-LAV) were
independently associated with an annual decline in
lung function in male patients with COPD. The CT-
based emphysema phenotype is associated with a
rapid decline in FEV1 and the severity of emphysema
increases the risk for a rapid decline [4,8]. However,
as far as we can ascertain, this is the first study to
prospectively demonstrate that a more homogeneous
distribution of emphysema contributes to an acceler-
ated decline in FEV1 independently of the severity of
emphysema.
The progression of COPD is heterogeneous [4,6-8].
Exploring risk factors for disease progression and
establishing the appropriate phenotype are important
to design a targeted strategy for preventing disease
progression. Radiographic phenotyping by CT hasFigure 3 A histogram of annual change in post-bronchodilator
FEV1.
Table 3 Prognostic factors contributing to annual
changes in FEV1 in multivariate random coefficient
model: Sub-analysis of 119 patients whose history of





Age, per 1-year increase 0.88 (0.04 to 1.71) 0.040
Height, per increase of
1 cm
0.13 (−1.06 to 1.31) 0.83
Weight, per increase of
1 kg
−0.09 (−1.00 to 0.81) 0.84
%FEV1, per 1% increase −0.87 (−1.44 to −0.31) 0.003
RV/TLC (%) 0.03 (−1.11 to 1.18) 0.95
DLCO/VA (mL/min/mmHg/L) −1.50 (−10.48 to 7.48) 0.74
Continuous smoking,
yes/no
−22.76 (−40.13 to −5.40) 0.011
LAV%, per 1% increase −2.62 (−4.04 to −1.20) 0.0004
SD-LAV, per 1% increase 3.32 (0.54 to 6.10) 0.020
WA%, per 1% increase −0.48 (−1.56 to 0.60) 0.26
Proxy for inspiration†,
per increase of 0.1




5.91 (−13.10 to 24.91) 0.54
Frequent exacerbation is defined as at least two exacerbations per year.
Abbreviations: %FEV1, percent predicted FEV1; RV/TLC, ratio of residual volume
to total lung capacity; DLCO/VA, ratio of diffusing capacity to alveolar
ventilation; LAV%, ratio of low attenuation volume to total lung volume;
SD-LAV, standard deviation of LAV% values in 10 partitions with equal
volumes; WA%, wall area percent in right apical bronchus;
†Proxy for inspiration was defined as the ratio of CT derived total lung volume
to physiologically-measured total lung capacity for estimating inspiration levels
during CT scan.
* Regression coefficients for interactions with time, negative value indicates
excess annual decline in FEV1.
Table 2 Prognostic factors contributing to annual change





Age, per 1-year increase 0.86 (0.10 to 1.63) 0.028
Height, per increase
of 1 cm
0.03 (−1.11 to 1.17) 0.96
Weight, per increase
of 1 kg
0.03 (−0.84 to 0.90) 0.95
%FEV1, per 1% increase −0.97 (−1.51 to −0.44) <0.0001
RV/TLC (%) 0.03 (−1.06 to 1.13) 0.95
DLCO/VA (mL/min/mmHg/L) −0.65 (−8.83 to 7.52) 0.88
Continuous smoking,
yes/no
−20.90 (−37.24 to −4.57) 0.013
LAV%, per 1% increase −2.46 (−3.81 to −1.10) <0.0001
SD-LAV, per 1% increase 3.24 (0.82 to 5.87) 0.016
WA%, per 1% increase −0.63 (−1.67 to 0.41) 0.23
Proxy for inspiration†,
per increase of 0.1
−1.67 (−7.36 to 4.01) 0.56
Abbreviations: %FEV1, percent predicted FEV1; RV/TLC, ratio of residual volume
to total lung capacity;
DLCO/VA, ratio of diffusing capacity to alveolar ventilation; LAV%, ratio of low
attenuation volume to total lung volume; SD-LAV, standard deviation of LAV%
values in 10 partitions with equal volumes;
WA%, wall area percent in right apical bronchus.
†Proxy for inspiration was defined as the ratio of CT-derived total lung volume
to physiologically measured total lung capacity for estimating inspiration levels
during CT scan.
*Regression coefficients for interactions with time, a negative value indicates
excess annual decline in FEV1..
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structural information that might reflect clinical
manifestations independently of conventional lung
function [14,16]. We previously showed that the se-
verity of emphysematous change predicts COPD
mortality independently of lung function [17]. The
present study found that a higher LAV% and a lower
SD-LAV contributed to an accelerated decline in
lung function independently of baseline %FEV1.
In addition to SD-LAV, we measured the difference
in LAV% between the upper and lower lung regions,
and found rather frequent lower predominant em-
physema in patients without an α1-antitrypsin defi-
ciency. This is consistent with previous reports, in
which smokers might not always have upper predom-
inant emphysema [20,21]. We considered that sus-
ceptibility to a rapid decline in lung function is
lower in patients with upper or lower predominant,
than homogeneous emphysema.
The determinants of emphysema distribution are not
fully understood, but genetic and environmental factors are
thought to be involved. Previous studies have shown that
variants of MMP-9 [22] or EPHX1 and GSTP1 [23] are
associated with upper-predominant emphysema. We
speculate that a currently unrecognized genetic backgroundis associated with susceptibility to homogenous emphy-
sema, and with a rapid decline in lung function. A compari-
son of clinical manifestations or genetic backgrounds
between homogeneous and heterogeneous emphysema
should increase understanding of the factors associated
with accelerated disease progression.
Airway dimensions were also analyzed because the
potential of CT-based categorization into emphysema-
and airway-dominant phenotypes has been suggested
[12-14]. Unlike LAV%, WA% in the proximal airway was
not associated with the annual decline in FEV1, although
proximal airway dimensions correlate with respiratory
symptoms, health-related quality of life and exacerba-
tion frequency [14,16,32]. We postulated that the rapid
decline in FEV1 is impacted more by the emphysema-
than the airway-dominant phenotype.
The present study showed that the mean annual
change in FEV1 was −44.4 mL. This is consistent with
the findings of two large clinical trials, in which the
annual decline in FEV1 was about 40 mL in the treat-
ment groups [3,5,33]. On the other hand, two recent
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32 to 33 mL per year [4,8]. Some COPD medications
such as tiotropium and salmeterol/fluticasone combin-
ation might reduce the decline in FEV1 [33,34], and the
present study reconfirmed that the baseline severity of
airflow limitation is inversely related to the decline in
FEV1.[4,7,33] We speculated that a difference in the
baseline characteristics could account for small discrep-
ancies among different studies.
The present study reconfirmed the deleterious effect
of smoking and the importance of smoking cessation.
Current smoking caused an additional 20.9 mL per
year decline in FEV1 (Table 2). This is consistent with
findings of other studies [4,35], in which the rate of
decline was 20–30 mL per year greater in current,
than in former smokers.
Exacerbation of COPD can cause a rapid decline in
FEV1 [4,33,36,37]. We therefore performed a sub-
analysis (Table 3), which included a history of fre-
quent exacerbations that can identify patients with
exacerbation susceptibility [38]. We found that SD-
LAV remained independently associated with a decline
in FEV1. However, the impact of a history of frequent
exacerbations was not detected. It have been shown
that exacerbations during follow-up are associated
with an additional decline in FEV1, but the number of
exacerbations in the previous year cannot predict the
future decline in FEV1 [4,33]. Thus, to further clarify
the relative contribution of the emphysema distribu-
tion and exacerbations to the decline in FEV1, a
model including exacerbations during follow-up
should be analyzed in future studies.
DLCO/VA and RV/TLC were also included in the present
random coefficient models. Tables 2 and 3 show that base-
line DLCO/VA and RV/TLC were not associated with the
subsequent change in FEV1. The lack of the association of
DLCO/VA with the decline in FEV1 in the model including
LAV% might have been because DLCO/VA correlates well
with LAV%. Indeed, when we constructed the other
random coefficient model including the same valuables
except LAV%, lower DLCO/VA tended to contribute to the
decline in FEV1 (p= 0.051).
Since inappropriate inspiration during CT scanning
can affect lung density, CT-derived total lung volume
has been used to adjust for the variability of the
inspiration level [16,39]. Previous studies have esti-
mated the inspiration level by assessing the ratio of
CT-derived total lung to predicted TLC [16,30]. We
modified this method in the present study. The ratio
of CT-derived total lung volume to TLC obtained by
lung function tests was calculated as the proxy for
inspiration level, and then the proxy was included
into the multivariate random coefficient model to
lessen this confounding effect.As shown in Supplementary Table E1 (Additional file 1),
the present random coefficient model included 14 (11%)
patients whose follow-up periods were less than 2 years.
Although patients who were lost to follow-up can be
generally included into the random coefficient model, we
perform subanalysis of 117 patients who were followed up
for at least two years. Consequently, we confirmed that
SD-LAV remained independently associated with annual
decline in FEV1 (p=0.009).
The limitations in the present study include a smaller
study population than those found in other studies [3-5].
However, we used the same scanner to increase
consistency among CT data and thus overcome the disad-
vantages of a small sample cohort. This strategy generated
valid information about the severity of emphysema and
the heterogeneity of cranial-caudal emphysema.
We could not recruit enough female patients to
explore the influence of sex on the decline in FEV1, and
thus excluded female patients in the present study. Since
susceptibility to cigarette smoke, the severity and distri-
bution of emphysema, and the extent of airway lesions
could differ between male and female patients [30,40,41],
the present findings cannot be generalized to female
patients with COPD.
The present study is observational, and COPD medica-
tions were selected by pulmonologists at Kyoto University
according to the GOLD guideline [1]. Some COPD medi-
cations such as salmeterol/fluticasone combination and
tiotropium might have modified the rate of change in
FEV1 [33,34]. However, we believe that this influence is
quite small because the relative contribution of LAV% and
SD-LAV to the change in FEV1 persisted after adjustment
for baseline %FEV1 and a history of exacerbations, which
could mainly affect the choice of COPD medication.
We measured airway dimensions in the proximal, but
not in the distal airways, although the major site of air-
way obstruction in patients with COPD is small airways
[42]. Since proximal airway dimensions assessed by CT
predict histological measurements of small-airway wall
dimensions [43], we believe that the location of the air-
ways in which we measured WA% impacted the present
results minimally or not at all.
Conclusion
We found that a more homogeneous distribution of
emphysema independently contributed to an accelerated
decline in lung function in addition to higher baseline
lung function, more severe emphysematous changes in
the whole lung, and current smoking. This not only
strengthens the value of the CT-based emphysema
phenotype as a predictor of a rapid decline in lung func-
tion, but also provides new information; a more homoge-
neous distribution of emphysema increases susceptibility
to rapid disease progression.
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Additional file 1: Supplementary tables for the present study. The
number of follow-up spirometry and follow-up period, regular COPD
medication during follow-up, and clinical course of study patients are
shown in supplementary table E1, E2, and E3, respectively.
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